Biosyent Inc. (RX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Biosyent Inc. (RX) has a cash flow conversion efficiency ratio of 0.069x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CA$2.77 Million ≈ $2.00 Million USD) by net assets (CA$39.90 Million ≈ $28.87 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See RX equity to assets ratio to measure how much of total assets are equity-financed.
Biosyent Inc. - Cash Flow Conversion Efficiency Trend (1997–2024)
This chart illustrates how Biosyent Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Biosyent Inc. (RX) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Biosyent Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biosyent Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
1911 Gold Corp
V:AUMB
|
-0.121x |
|
QES Group Bhd
KLSE:0196
|
0.036x |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
0.000x |
|
InflaRx N.V
F:IF0
|
-0.113x |
|
Amber International Holding Limited
NASDAQ:AMBR
|
-0.008x |
|
Paxman AB
ST:PAX
|
-0.014x |
|
Hanyang Digitech Co. Ltd
KQ:078350
|
0.037x |
|
Servotronics Inc
NYSE MKT:SVT
|
-0.067x |
Annual Cash Flow Conversion Efficiency for Biosyent Inc. (1997–2024)
The table below shows the annual cash flow conversion efficiency of Biosyent Inc. from 1997 to 2024. For the full company profile with market capitalisation and key ratios, see RX market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | CA$35.00 Million ≈ $25.32 Million |
CA$8.66 Million ≈ $6.27 Million |
0.248x | +47.68% |
| 2023-12-31 | CA$34.76 Million ≈ $25.14 Million |
CA$5.83 Million ≈ $4.21 Million |
0.168x | +12.99% |
| 2022-12-31 | CA$33.36 Million ≈ $24.13 Million |
CA$4.95 Million ≈ $3.58 Million |
0.148x | +0.12% |
| 2021-12-31 | CA$31.55 Million ≈ $22.83 Million |
CA$4.67 Million ≈ $3.38 Million |
0.148x | -42.42% |
| 2020-12-31 | CA$26.80 Million ≈ $19.38 Million |
CA$6.89 Million ≈ $4.99 Million |
0.257x | +39.11% |
| 2019-12-31 | CA$25.79 Million ≈ $18.66 Million |
CA$4.77 Million ≈ $3.45 Million |
0.185x | -18.78% |
| 2018-12-31 | CA$27.61 Million ≈ $19.97 Million |
CA$6.29 Million ≈ $4.55 Million |
0.228x | -22.73% |
| 2017-12-31 | CA$22.21 Million ≈ $16.07 Million |
CA$6.55 Million ≈ $4.74 Million |
0.295x | +12.06% |
| 2016-12-31 | CA$16.73 Million ≈ $12.10 Million |
CA$4.40 Million ≈ $3.18 Million |
0.263x | +13.69% |
| 2015-12-31 | CA$12.15 Million ≈ $8.79 Million |
CA$2.81 Million ≈ $2.03 Million |
0.231x | -48.14% |
| 2014-12-31 | CA$8.16 Million ≈ $5.90 Million |
CA$3.64 Million ≈ $2.63 Million |
0.446x | +2.20% |
| 2013-12-31 | CA$4.85 Million ≈ $3.51 Million |
CA$2.12 Million ≈ $1.53 Million |
0.436x | -0.79% |
| 2012-12-31 | CA$2.84 Million ≈ $2.05 Million |
CA$1.25 Million ≈ $903.61K |
0.440x | -14.20% |
| 2011-12-31 | CA$1.16 Million ≈ $840.98K |
CA$596.08K ≈ $431.19K |
0.513x | +807.97% |
| 2010-12-31 | CA$671.02K ≈ $485.40K |
CA$37.89K ≈ $27.41K |
0.056x | +110.00% |
| 2009-12-31 | CA$607.02K ≈ $439.11K |
CA$-342.79K ≈ $-247.97K |
-0.565x | -85.44% |
| 2008-12-31 | CA$854.08K ≈ $617.83K |
CA$-260.09K ≈ $-188.15K |
-0.305x | -2495.85% |
| 2007-12-31 | CA$1.12 Million ≈ $810.93K |
CA$14.25K ≈ $10.31K |
0.013x | -92.99% |
| 2006-12-31 | CA$1.23 Million ≈ $886.46K |
CA$222.26K ≈ $160.78K |
0.181x | -80.32% |
| 2005-12-31 | CA$811.46K ≈ $587.00K |
CA$747.81K ≈ $540.95K |
0.922x | +370.31% |
| 2004-12-31 | CA$306.20K ≈ $221.50K |
CA$-104.39K ≈ $-75.52K |
-0.341x | +66.97% |
| 2003-12-31 | CA$606.86K ≈ $438.99K |
CA$-626.35K ≈ $-453.09K |
-1.032x | -170.90% |
| 2002-12-31 | CA$621.73K ≈ $449.75K |
CA$905.12K ≈ $654.75K |
1.456x | +527.53% |
| 2001-12-31 | CA$990.86K ≈ $716.77K |
CA$-337.40K ≈ $-244.07K |
-0.341x | +43.18% |
| 2000-12-31 | CA$210.36K ≈ $152.17K |
CA$-126.07K ≈ $-91.20K |
-0.599x | -79.79% |
| 1999-12-31 | CA$600.00K ≈ $434.03K |
CA$-200.00K ≈ $-144.68K |
-0.333x | +63.33% |
| 1998-12-31 | CA$1.10 Million ≈ $795.72K |
CA$-1.00 Million ≈ $-723.38K |
-0.909x | -13.64% |
| 1997-12-31 | CA$500.00K ≈ $361.69K |
CA$-400.00K ≈ $-289.35K |
-0.800x | -- |
About Biosyent Inc.
BioSyent Inc., together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form produc… Read more